Study of NNC0487-0111 Weekly Injections for Adults with Overweight or Obesity and Knee Osteoarthritis to Help Lose Weight and Reduce Pain

What this Trial Is About

Researchers are evaluating the safety and effects of NNC0487-0111 in adults with excess body weight and knee osteoarthritis. This study compares the active treatment with a placebo injection given once weekly. The goal is to assess weight loss and pain reduction over a long-term period, as well as other health measures related to osteoarthritis and metabolic health. Participants are randomly assigned to receive one of two dose levels of NNC0487-0111 or a placebo injection, both administered under the skin once a week. These injections are given alongside a reduced-calorie diet and increased physical activity. The treatment period lasts up to 80 weeks, during which participants follow the specified lifestyle changes. Throughout the study, participants will have regular assessments including body weight, knee pain and function scores WOMAC, physical functioning, blood pressure, cholesterol levels, blood sugar control HbA1c and fasting glucose, and use of pain medications. Safety events and adverse reactions are monitored up to week 84. Participants will be followed closely with these measurements to evaluate the treatments impact and overall safety.

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain